Allspring Global Investments
INZY

Allspring Global Investments’s Inozyme Pharma INZY Stock Holding History

Allspring Global Investments’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66
Closed -$345 – 2079
2024
Q3 		$345 Hold
66
– – ﹤0.01% 2385
2024
Q2 		$294 Buy
+66
New +$320 ﹤0.01% 2333

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allspring Global Investments's INZY Position: Q4 2024 in Review

Allspring Global Investments sold out of Inozyme Pharma (INZY) in Q4 2024, closing a stake of 66 shares — an estimated $345 sold.

Allspring Global Investments first reported a position in INZY in Q2 2024 and held it in 2 quarters. The position peaked at $345 in Q3 2024. 105 funds tracked by Wall St. Rank hold INZY as of Q4 2024.

  • Allspring Global Investments reported no remaining Inozyme Pharma position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 66 Inozyme Pharma shares in Q4 2024, an estimated $345.
  • Allspring Global Investments first reported a position in Inozyme Pharma in Q2 2024 and held it in 2 quarters.
  • Allspring Global Investments's Inozyme Pharma position peaked at $345 in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.